How Long Does It Take for the RSV Vaccine to Work?

RSV vaccines begin generating a measurable immune response within days, but the protection that matters clinically takes roughly two weeks to develop. By day 14 or 15 after vaccination, neutralizing antibody levels in the blood have risen sharply, and large effectiveness studies use a 14-day cutoff to classify someone as “vaccinated.” That does not mean the vaccine flips a switch on day 14 and you are fully protected. The immune buildup is gradual, and the strength of that protection changes over weeks and months in ways that depend on your age, immune health, and even which vaccine platform you received.

Why Fourteen Days Is the Standard Benchmark

If you look at the clinical trials and real-world effectiveness studies behind the approved RSV vaccines, you will see the same number come up repeatedly: 14 days. In one of the pivotal trials for the Ad26.RSV.preF vaccine in older adults, neutralizing antibody titers against RSV A2 jumped roughly 12-fold from baseline by day 15.¹ That is a dramatic rise in a short window, and it is consistent across the different vaccine types that have been studied.

Real-world effectiveness studies reinforce this timeline. A multi-season analysis of RSV vaccine effectiveness among U.S. adults aged 60 and older excluded anyone who received the vaccine fewer than 14 days before getting sick, and defined “vaccinated” as having received a dose at least 14 days prior to illness onset.² Another study from the same network used the same 14-day threshold.³ These choices are not arbitrary. Researchers draw the line there because the immune system simply has not mounted enough of a response before that point to reliably change outcomes.

What Happens Inside Your Body During Those Two Weeks

When you receive an RSV vaccine, the key target is the fusion protein (called the F protein) on the surface of the virus. The vaccine presents a stabilized version of this protein, most often in its prefusion shape, to your immune system. Your B cells recognize the protein and begin producing antibodies against it, while T cells ramp up to coordinate the broader immune response.

In a human challenge study tracking what happens after RSV exposure, activated CD4+ T cells in the blood peaked around day 10, coinciding with viral clearance.⁴ That study looked at natural infection rather than vaccination, but the timeline is instructive: the cellular arm of immunity takes about a week and a half to fully mobilize. Meanwhile, neutralizing antibodies, the molecules that physically block the virus from entering your cells, are climbing rapidly from about day 7 onward and reach a meaningful plateau somewhere around day 14 to 28.

For the protein-based vaccines studied in older adults, one formulation showed that anti-F antibody levels peaked about 14 days after the shot, with certain adjuvant combinations extending that peak response for four to five weeks.⁵ This means the first two weeks are the steep upward climb, and the following two to three weeks represent a stabilization phase where your protection is near its highest.

Peak Protection and How It Compares to Later Months

The first month after vaccination is when your defense is strongest. Data from an mRNA-based RSV vaccine trial in older adults showed that at one month post-vaccination, neutralizing antibody levels against RSV-A rose at least 10-fold from baseline, and against RSV-B at least 5-fold. Those elevated levels persisted above baseline through 12 months, though they gradually declined: by the one-year mark, the fold-rise over baseline had dropped to roughly 2.4 for RSV-A and 1.5 for RSV-B.⁶

Those immunological numbers translate into real-world protection patterns. A large study of U.S. veterans found that vaccine effectiveness against documented RSV infections was about 83% in the first month. Over 18 months, that number dropped to about 59%. A similar pattern held for more severe outcomes: effectiveness against hospitalizations started near 89% and fell to roughly 57%, while protection against ICU admissions went from about 93% to 72%.⁷ The vaccine clearly keeps working well beyond the first few weeks, but the sharpest protection is in those early months.

Why Protection Fades and What That Means for Timing

The decline in vaccine-induced protection mirrors what happens after natural RSV infection. Even people who catch RSV and recover see their antibody levels drop substantially: in one study tracking adults after natural infection, antibody titers fell at a rate that resulted in a four-fold or greater decline within a year for three-quarters of participants.⁸ This is partly why people can get RSV repeatedly throughout their lives, unlike diseases where one infection grants lasting immunity.

This natural waning has a practical implication for vaccination timing. Because protection is strongest in the first several months, getting vaccinated just before or at the beginning of RSV season gives you the best odds. In most of the United States, RSV season typically runs from fall through early spring, with a peak in winter. If you get the shot in late summer or early fall, your antibody levels will be at their highest during the months when you are most likely to encounter the virus. Getting vaccinated in March for a season that does not start until October means several months of antibody decline before you actually need the protection.

This question of timing is even more important in settings outside the United States. Modeling work for lower-income countries, where RSV seasonality can differ, has explored strategies that begin immunization one to three months before the local epidemic starts to ensure infants and older adults have adequate protection when transmission peaks.⁹

Maternal RSV Vaccination Has a Different Clock

For pregnant people receiving the RSV vaccine (Abrysvo), the goal is not to protect themselves but to transfer protective antibodies to the baby across the placenta. This adds a completely different dimension to the “how long does it take” question, because it is not just about generating antibodies but about getting them into the baby’s bloodstream efficiently before birth.

Research on placental antibody transfer shows that the interval between vaccination and delivery matters a great deal. When vaccination occurred only two to three weeks or three to four weeks before delivery, the ratio of antibodies in cord blood compared to maternal blood was significantly lower than when vaccination happened more than five weeks before delivery.¹⁰ In other words, even though the mother’s antibody levels are rising quickly in those first two weeks, the placenta needs more time to actively pump those antibodies across to the fetus. Vaccinating too close to delivery means the baby may be born before enough antibodies have been transferred, even if the mother’s own levels are high.

This is why the recommended vaccination window for pregnant individuals is during weeks 32 through 36 of pregnancy. That timing balances giving the mother enough weeks to generate a strong antibody response while also allowing enough time for placental transfer before the baby arrives. Getting vaccinated earlier in pregnancy would give even more transfer time, but the antibodies might wane before the baby is born and needs them most during their vulnerable first months of life.

People With Weakened Immune Systems Respond More Slowly

Not everyone’s immune system reacts to the vaccine on the same schedule. For people with blood cancers or other conditions that suppress the immune system, the antibody response after RSV vaccination is weaker and fades faster. A study comparing vaccine responses in people with hematological malignancies to healthy controls found that while both groups showed an increase in antibodies at one month, the absolute antibody levels in the immunocompromised group were dramatically lower. For RSV-A, median titers at one month were roughly ten times lower in patients with blood cancers compared to healthy people. Worse, the response waned more quickly: RSV-A antibodies stayed above baseline at three months in the immunocompromised group, but RSV-B antibodies did not even make it past the one-month mark.¹¹

Even among generally healthy older adults, aging takes a toll on vaccine responses. One study of an older protein-based RSV vaccine formulation in adults 60 and older found that antibody levels rose only about 1.5 times from baseline by day 29, and neutralizing titers roughly doubled.⁵ Compare that to the 10- to 12-fold jumps seen in healthier or younger trial populations, and it is clear that age-related immune decline meaningfully affects both the speed and magnitude of the vaccine response. This does not mean the vaccine is useless in older adults — real-world effectiveness data shows it still prevents hospitalizations — but the protective ceiling may be lower and may be reached somewhat later.

Prior RSV Exposure Can Prime a Faster Response

One factor that works in most adults’ favor is that virtually everyone has been infected with RSV before, usually many times. This matters because the immune system retains some memory of the virus, and the vaccine essentially serves as a booster for that existing memory rather than building immunity from scratch.

Animal research has shown that prior RSV infection effectively primes the immune system so that a subsequent vaccination with prefusion F protein can rapidly activate the production of protective antibodies. Interestingly, a second natural RSV infection did not produce the same efficient boost, but the vaccine formulation did.¹² This helps explain why the immune response to RSV vaccines in adults is so fast — within two weeks, memory B cells are being rapidly recalled and expanded, rather than being created for the first time.

This also means the 14-day timeline researchers use is partly a reflection of the adult immune landscape. For a hypothetical RSV-naive person (which essentially does not exist among adults), the response would likely be slower. But for anyone who has encountered RSV before, which is nearly everyone by age two, the vaccine is tapping into a pre-existing reservoir of immune memory.

Getting the RSV Vaccine with a Flu Shot or Other Vaccines

A practical question many people have is whether getting the RSV vaccine at the same time as their annual flu shot affects how quickly or how well either vaccine works. The evidence here is reassuring. A clinical trial that tested co-administration of an RSV F protein nanoparticle vaccine with a standard-dose flu vaccine found no interference in either direction: flu antibody responses were unaffected by the RSV vaccine, and RSV antibody responses were unaffected by the flu vaccine.¹³ This means the two-week timeline for RSV protection holds even if you are getting both shots in the same visit.

Getting both vaccines at once is convenient, especially since the ideal timing for each overlaps: both work best when given before their respective seasons hit. For most adults, scheduling them together in early fall covers both bases without adding an extra appointment.

The Role of Mucosal Immunity

Most discussions of how quickly the RSV vaccine works focus on antibodies circulating in the blood, because those are the easiest to measure. But RSV is a respiratory virus that enters through the nose and airways, so the mucosal immune response — antibodies present in the lining of the respiratory tract — is a critical layer of defense that blood tests do not fully capture.

Research from a high-burden setting found that mucosal IgA antibodies directed at the prefusion F protein were actually the strongest predictor of protection against RSV infection, outperforming blood-based IgG antibodies. After natural infection, mucosal IgA showed a stronger boost (about a 6-fold rise) and lasted longer above meaningful levels (around 220 days) compared to serum IgG (which rose about 4-fold and stayed elevated for about 175 days).¹⁴ These findings come from natural infection rather than vaccination, and the current approved RSV vaccines are injected into muscle rather than delivered to the nose, so they may not generate the same robust mucosal IgA response.

This is an active area of research. Intranasal RSV vaccine candidates are in development precisely because of this gap. For now, the injectable vaccines rely primarily on blood-borne antibodies that can seep into the respiratory tract, which is effective at preventing severe disease and hospitalization even if it may be less effective at preventing mild upper respiratory infections. The practical takeaway: even once your blood antibody levels are fully up after two weeks, your mucosal defenses may not be at their peak, and this could explain why vaccinated people sometimes still catch mild RSV illness.

How Much Antibody Is Enough

A question that researchers have wrestled with is what level of neutralizing antibodies you actually need to be protected. Unlike some vaccines where a single threshold number clearly separates “protected” from “unprotected,” RSV immunity is more of a gradient. Higher antibody levels correlate with better protection, but there is no absolute cutoff below which you are guaranteed to get sick.

One study that tried to establish minimum protective thresholds found that for every doubling of neutralizing antibody titer against RSV-A, the likelihood of avoiding RSV-related hospitalization increased by about 22%. The researchers identified a minimum protective threshold titer against RSV-A that, when exceeded, was associated with roughly 3.5 times the odds of avoiding hospitalization compared to being below it.¹⁵ This gradient relationship matters for understanding the timeline question, because your protection does not snap into place at one moment. It increases steadily as antibody levels climb during the first two weeks and continues to strengthen as levels stabilize around one month. Similarly, as antibodies wane over the following months, your risk does not suddenly jump back to unvaccinated levels — it rises slowly.

This gradual relationship also explains why the vaccine remains useful even at 18 months when effectiveness numbers have dropped. A 57-to-60% effectiveness against hospitalization, while lower than the initial 89%, is still meaningfully better than no vaccination at all. Your antibodies are still above that threshold; they are just no longer as far above it as they were in month one.

Boosters and the Question of a Second Dose

Given that protection wanes over time, the natural follow-up is whether a booster dose can restore it. Early data from the mRNA vaccine trial showed that a booster given at 12 months did reactivate immunity, pushing neutralizing antibody levels back up to fold-rises of 7 to 12 for RSV-A and 4 to 9 for RSV-B over baseline.⁶ Those numbers are broadly similar to the response seen after the first dose, suggesting the immune memory primed by the initial vaccination is still intact and ready to be recalled.

As of mid-2025, the CDC has not recommended routine annual RSV revaccination for all adults, though the question is under active review as more durability data accumulates. The current guidance for adults 60 and older is a single dose, with discussions about a second season dose still ongoing. For people who were vaccinated more than a year ago and are heading into another RSV season, this is an area worth watching for updated recommendations.